GSK 3039294Alternative Names: GSK-3039294
Latest Information Update: 23 Dec 2016
At a glance
- Originator GlaxoSmithKline
- Class Neuroprotectants
- Mechanism of Action Serum amyloid P component inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Phase I Amyloidosis
Most Recent Events
- 20 Nov 2015 Preclinical trials in Amyloidosis in United Kingdom (PO) before November 2015
- 20 Nov 2015 GSK plans a phase I trial for Amyloidosis in United Kingdom (NCT02603172)